Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs is attractive because its DR3-focused platform appears biologically validated by healthy-volunteer SL-325 data showing a 3.7% ADA rate, full receptor occupancy even at 0.1 mg/kg, and only Grade 1 treatment-related adverse events, which together de-risk its differentiated mechanism versus anti-TL1A competitors. The planned RECEPTIVE-CD1 Phase 2b Crohn’s study in 3Q26, expanded to about 232 patients across three dose levels, plus the new HS program and SL-846 bispecific, create multiple shots on goal that could expand the addressable opportunity beyond IBD. Financially, the company ended 2Q26 with $208.3 million in cash and management expects that to fund operations into 2029, giving it runway to execute without near-term financing pressure.

Shattuck Labs is facing a fundamentally difficult outlook because its preclinical assets may fail to advance into clinical studies, and even successful development would enter highly competitive TL1A and inflammatory bowel disease markets already crowded with large pharma and biotech rivals. The company also must differentiate SL-325 and related programs against approved, well-established UC and Crohn’s therapies while building commercial infrastructure it currently lacks, increasing execution risk and pressure on future uptake. Financially, profitability is not expected for several years, clinical timelines require significant capital, and additional financing may be needed on unfavorable terms, while patent protection and legal exposure remain uncertain.